These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

461 related items for PubMed ID: 27349615

  • 1. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force.
    Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijer K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I.
    Eur Urol; 2017 Apr; 71(4):648-655. PubMed ID: 27349615
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The Transatlantic Recommendations for Prostate Gland Evaluation with Magnetic Resonance Imaging After Focal Therapy (TARGET): A Systematic Review and International Consensus Recommendations.
    Light A, Mayor N, Cullen E, Kirkham A, Padhani AR, Arya M, Bomers JGR, Dudderidge T, Ehdaie B, Freeman A, Guillaumier S, Hindley R, Lakhani A, Pendse D, Punwani S, Rastinehad AR, Rouvière O, Sanchez-Salas R, Schoots IG, Sokhi HK, Tam H, Tempany CM, Valerio M, Verma S, Villeirs G, van der Meulen J, Ahmed HU, Shah TT.
    Eur Urol; 2024 May; 85(5):466-482. PubMed ID: 38519280
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group.
    Moore CM, Kasivisvanathan V, Eggener S, Emberton M, Fütterer JJ, Gill IS, Grubb Iii RL, Hadaschik B, Klotz L, Margolis DJ, Marks LS, Melamed J, Oto A, Palmer SL, Pinto P, Puech P, Punwani S, Rosenkrantz AB, Schoots IG, Simon R, Taneja SS, Turkbey B, Ukimura O, van der Meulen J, Villers A, Watanabe Y, START Consortium.
    Eur Urol; 2013 Oct; 64(4):544-52. PubMed ID: 23537686
    [Abstract] [Full Text] [Related]

  • 6. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting.
    Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B, Futterer JJ, Heijmink SW, Hoskin PJ, Kirkham A, Padhani AR, Persad R, Puech P, Punwani S, Sohaib AS, Tombal B, Villers A, van der Meulen J, Emberton M.
    Eur Urol; 2011 Apr; 59(4):477-94. PubMed ID: 21195536
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training.
    de Rooij M, Israël B, Tummers M, Ahmed HU, Barrett T, Giganti F, Hamm B, Løgager V, Padhani A, Panebianco V, Puech P, Richenberg J, Rouvière O, Salomon G, Schoots I, Veltman J, Villeirs G, Walz J, Barentsz JO.
    Eur Radiol; 2020 Oct; 30(10):5404-5416. PubMed ID: 32424596
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Update on Multiparametric Prostate MRI During Active Surveillance: Current and Future Trends and Role of the PRECISE Recommendations.
    Giganti F, Kirkham A, Allen C, Punwani S, Orczyk C, Emberton M, Moore CM.
    AJR Am J Roentgenol; 2021 Apr; 216(4):943-951. PubMed ID: 32755219
    [Abstract] [Full Text] [Related]

  • 12. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
    Oprea-Lager DE, MacLennan S, Bjartell A, Briganti A, Burger IA, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillessen S, Herrmann K, Heskamp S, Iagaru A, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, Sala E, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J, Yakar D, Dierckx R, Sartor O, Fanti S.
    Eur Urol; 2024 Jan; 85(1):49-60. PubMed ID: 37743194
    [Abstract] [Full Text] [Related]

  • 13. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force.
    Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, Van den Bergh R, Van Poppel H, Valdagni R, Bellardita L.
    Eur Urol; 2017 Feb; 71(2):274-280. PubMed ID: 27720532
    [Abstract] [Full Text] [Related]

  • 14. Clinical Application of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation Score for Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer.
    Aerts J, Hendrickx S, Berquin C, Lumen N, Verbeke S, Villeirs G, Van Praet C, De Visschere P.
    Eur Urol Open Sci; 2023 Oct; 56():39-46. PubMed ID: 37822515
    [Abstract] [Full Text] [Related]

  • 15. Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis.
    Rajwa P, Pradere B, Quhal F, Mori K, Laukhtina E, Huebner NA, D'Andrea D, Krzywon A, Shim SR, Baltzer PA, Renard-Penna R, Leapman MS, Shariat SF, Ploussard G.
    Eur Urol; 2021 Nov; 80(5):549-563. PubMed ID: 34020828
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness Analysis of Active Surveillance Strategies for Men with Low-risk Prostate Cancer.
    Sathianathen NJ, Konety BR, Alarid-Escudero F, Lawrentschuk N, Bolton DM, Kuntz KM.
    Eur Urol; 2019 Jun; 75(6):910-917. PubMed ID: 30425010
    [Abstract] [Full Text] [Related]

  • 17. Interobserver reproducibility of the PRECISE scoring system for prostate MRI on active surveillance: results from a two-centre pilot study.
    Giganti F, Pecoraro M, Stavrinides V, Stabile A, Cipollari S, Sciarra A, Kirkham A, Allen C, Punwani S, Emberton M, Catalano C, Moore CM, Panebianco V.
    Eur Radiol; 2020 Apr; 30(4):2082-2090. PubMed ID: 31844959
    [Abstract] [Full Text] [Related]

  • 18. Role of Changes in Magnetic Resonance Imaging or Clinical Stage in Evaluation of Disease Progression for Men with Prostate Cancer on Active Surveillance.
    Chesnut GT, Vertosick EA, Benfante N, Sjoberg DD, Fainberg J, Lee T, Eastham J, Laudone V, Scardino P, Touijer K, Vickers A, Ehdaie B.
    Eur Urol; 2020 Apr; 77(4):501-507. PubMed ID: 31874726
    [Abstract] [Full Text] [Related]

  • 19. mpMRI Interpretation in Active Surveillance for Prostate Cancer-An overview of the PRECISE score.
    Harder FN, Heming CAM, Haider MA.
    Abdom Radiol (NY); 2023 Jul; 48(7):2449-2455. PubMed ID: 37160473
    [Abstract] [Full Text] [Related]

  • 20. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer: rationale and design.
    Ahlberg MS, Adami HO, Beckmann K, Bertilsson H, Bratt O, Cahill D, Egevad L, Garmo H, Holmberg L, Johansson E, Rannikko A, Van Hemelrijck M, Jäderling F, Wassberg C, Åberg UWN, Bill-Axelson A.
    BMJ Open; 2019 Aug 22; 9(8):e027860. PubMed ID: 31444180
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.